Novartis $12bn bet on Avidity well placed after mid-stage FSHD win

Novartis-owned Avidity Biosciences is currently evaluating del-brax in a recruiting Phase III study in FSHD. A readout is expected in Q3 2028 Novartis-owned Avidity Biosciences is currently evaluating del-brax in a recruiting Phase III study in FSHD. Novartis’ del-brax is currently in Phase III for FSHD. Credit: Dan76 / Shutterstock.com. Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets, delpacibart braxlosiran (del-brax), has posted a mid-stage win in the rare muscle wasting disease facioscapulohumeral muscular dystrophy (FSHD). In the Phase I/II FORTITUDE study (NCT05747924), Avidity investigated the safety, pharmacokinetics (PK) and…

Source: Clinical Trials Arena